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cell survival and stimulating the production of pro-
infl ammatory cytokines such as interferon-γ and 
interleukin (IL)-2. Recent evidence demonstrates 
a detrimental involvement of leptin in promoting 
the pathogenesis of various autoimmune diseases. 
In respect of its diverse functions in immunity, 
leptin has been explored as a potential target for 
therapeutic development in treating autoimmune 
diseases.5
 Systemic lupus erythematosus (SLE) is an 
autoimmune rheumatic disease characterized 
by widespread infl ammation affecting virtually 
every organ or system in the body. The disease is 
associated with the deposition of auto antibodies 
and immune complexes, leading to tissue 
damage.6 Role of leptin in pathogenesis of SLE is 
not fully understand yet. A cross-sectional study 
conducted by Garcia-Gonzales et al found that 
patients with SLE had higher leptin serum leptin 
concentration than control group.1 A borderline 
negative correlation was observed between leptin 
concentration and disease activity (Mexican SLE 
disease activity index [Mex-SLEDAI] score), 
but not statistically signifi cant. Selection of 
the subjects in their study wasn’t based on the 
classifi cation of body mass index (BMI) and 
menopausal status, so the study result might be 
interfered by those variables. The aim of this 
cross-sectional study is to determine correlation 
between serum leptin concentration and disease 
activity in SLE premenopausal women with 
normal BMI.
MATERIALS AND METHODS
Characteristic of systemic lupus erythematosus 
patients
Seventy SLE premenopausal women with normal 
BMI according to Asia-Pacifi c criteria were 
included in the study, all of whom gave written 
consent.7 The SLE patients were diagnosed 
according to the revised American College of 
Rheumatology criteria.8,9 Subjects were collected 
from outpatient unit Department of Internal 
Medicine, Cipto Mangunkusumo Hospital and 
Yayasan Lupus Indonesia in Jakarta. The approval 
of the Local Ethical Committee to carry out the 
research had been obtained before. 
ABSTRACT
Background. Leptin is recognized as a cytokine-like 
hormone with pleiotropic actions in modulating immune 
responses. The role of leptin in pathogenesis of systemic 
lupus erythematosus (SLE) was not fully understood yet. 
Previous study did not fi nd the correlation between serum 
leptin concentration and disease activity in patients with 
SLE, but selection of the subjects wasn’t based on the 
classifi cation of body mass index (BMI) and menopausal 
status.
Objective.  To determine correlation between serum 
leptin concentration and the disease activity in normal 
BMI premenopausal women with SLE.
Methods. Serum leptin concentration was measured 
by enzyme-linked immunosorbent assay and disease 
activity was scored using Mexican SLE disease activity 
index (Mex-SLEDAI). Spearman’s correlation coeffi cient 
test was used for evaluating the strength of association 
between leptin level and Mex-SLEDAI score. 
Results. Seventy normal BMI premenopausal women 
with SLE were included in this study. The median of 
serum leptin concentration was 13.4 (0.6 – 45.9) ng/ml. 
The median serum leptin concentration in patients with 
active disease was 12.4 (0.6 – 41.6) ng/dl, whereas in 
patients with inactive disease was 15.2 (3.9 – 45.9) ng/dl. 
No signifi cant different was found between serum leptin 
concentration in active and inactive disease (p = 0.14). A 
weak negative correlation was observed between leptin 
concentration and Mex-SLEDAI score, but not statistically 
signifi cant (r = -0.22; p = 0.07).
Conclusion. No correlation was found between serum 
leptin concentration and disease activity in normal BMI 
premenopausal women with SLE. Prednisone doses and 
disease duration might interfere.
Leptin constitutes a hormone synthesized by the 
adipose tissue that binds with a receptor which is 
a member of the class I cytokine receptor family.1-
4 Leptin has been increasingly recognized as a 
cytokine-like hormone with pleiotropic actions in 
modulating immune responses. Leptin can activate 
monocytes, dendritic cells and macrophages then 
stimulate them to produce Th1 type cytokines. 
Leptin also exerts activating effects on neutrophils 
and natural killer cells and stimulate their gene 
expressions. Importantly, leptin has been shown to 
modulate the adaptive immunity by enhancing T 
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Table 2   Serum leptin concentration based on disease activity
Disease activity n Median (range) p value*
Active 40 12.4 (0.6 – 41.6) 0.14
Inactive 30 15.2 (3.9 – 45.9)
*Comparison made with the Mann-Whitney U test
 
 Serum leptin concentration or score Mex-SLEDAI between 
SLE patients who only got prednisone therapy and combination 
therapy (prednisone and others immunosuppressant) was not 
signifi cantly different, as shown in table 3 (p = 0.49 and p = 
0.79, respectively).
Table 3   Serum leptin concentration and Mex-SLEDAI score based on 
kind of therapy
Parameter Kind of therapy P value*
Prednisone only Combination
Median (range) Median (range)
Serum leptin concentration 12.35 (0.70-45.86) 16.39 (0.62-42.39) 0.49
Mex-SLEDAI score 2 (0-12) 2 (0-10) 0.79
 *Comparisons made with the Mann-Whitney U test
 Using Spearman’s correlation test, a weak negative 
correlation was observed between serum leptin concentration 
and Mex-SLEDAI score, but was not statistically signifi cant, 
as shown in fi gure 1 (r = -0.22,   p = 0.07) .
Figure 1   Correlation between serum leptin concentration and Mex-
SLEDAI score in normal body mass index premenopausal women with 
systemic lupus erythematosus 
 
 Systemic lupus erythematosus patients with renal disorder 
or vasculitis had lower serum leptin concentration than 
patients without this symptom, whereas SLE patients with 
arthritis or mucocutaneous disorder had higher serum leptin 
concentration than patients without this symptom. However, 
all of this different were not statistically signifi cant (table 4).
 Patients with diabetes mellitus, hypertension, chronic 
renal failure, hyperthyroidism, malignancy, pregnancy, 
oral contraceptive therapy, severe infection at the time of 
assessment, history of surgery within a month before initiation 
of the study or smoking habit were excluded. Included in the 
assessment were clinical variables such as age, body mass 
index, disease duration, mean of daily prednisone doses in the 
previous month and disease activity according to the Mex-
SLEDAI.10 Patients with a Mex-SLEDAI score greater than or 
equal to 2 points were considered active while inactive disease 
if the score was less than 2 points.11
Serum leptin concentration evaluation
Serum leptin concentration was measured by enzyme-linked 
immunosorbent assay (Quantikine, R&D systems, Inc., 
Abingdon, USA). Blood samples were taken after at least 12 
hours overnight fasting. The serum was frozen at -20oC until 
the analysis of leptin concentration. All procedures for the 
measurement of leptin were made by the same researcher.
Statistical analysis
Statistical analysis were done using SPSS version 13. 
Considering that leptin concentration was abnormally 
distributed, we used the medians and ranges for statistical 
comparisons. Spearman’s correlation coeffi cient test was 
used for evaluating the strength of association between leptin 
concentration and disease activity. The Mann-Whitney U-test 
was used for comparisons between the leptin concentration 
in patients with active and inactive disease. Statistical 
signifi cance was set at the < 0.05 level.
RESULTS
Serum leptin concentration in SLE patients range from 0.6 to 
45.9 ng/ml with median of 13.4 ng/ml. The median disease 
duration was two years (range : 0.2 to 18 years), the median 
daily doses of prednisone was 10 mg (range : 0 to 55 mg) and 
the median Mex-SLEDAI score was 2 (range : 0 to 12). These 
variables distribution was shown in table 1.
Table 1  Characteristic distribution of systemic lupus erythematosus patients
Characteristics Median (range)*
Age (years) 26 (16 – 46)
BMI (kg/m2) 21.1 (18.6 – 22.9)
Disease duration (years) 2   (0.2 – 18)
Prednisone doses (mg/day) 10 (0 – 55)
Mex-SLEDAI score 2   (0 – 12)
Serum leptin concentration (ng/ml) 13.4 (0.6 – 45.9)
* Data are abnormally distributed
 Of all the subjects, 40 (57%) patients had active disease 
(Mex-SLEDAI score ≥ 2 points) and 30 (43%) patients had 
inactive disease (Mex-SLEDAI < 2 points). Patients with 
active disease had lower of serum leptin concentration than 
patients with inactive disease, but the difference was not 
statistically signifi cant, as shown in table 2 (p = 0.14).
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Table 4   Serum leptin concentration based on the clinical picture
Symptoms Serum leptin concentration
[Median (range)]
p value*
Symptom present Symptom absent
Arthritis (n = 6) 17.15
(2.53 – 29.2)
13.39
(0.62 – 45.86)
0.97
Mucocutaneous 
disorder (n = 16)
19.48
(0.62 – 41.62)
11.75
(0.7 – 45.86)
0.06
Hematologic 
disorder (n = 5)
11
(0.62 – 19.1)
13.53
(0.7 – 45.86)
0.31
Renal disorder (n 
= 20)
11.03
(1.25 – 41.62)
16.23
(0.62 – 45.86)
0.09
Vasculitis (n = 9) 4.19
(1.25 – 30.8)
14.56
(0.62 – 45.86)
0.05
*Comparisons made with the Mann-Whitney U test
Analysis of confounding variables
Prednisone doses and disease duration might take place as 
confounding variables. By using Spearman’s correlation 
coeffi cient test showed that the main variables (serum leptin 
concentration and Mex-SLEDAI score) correlated with 
confounding variables (table 5).
Table 5   Correlation between main and confounding variables
Main variables Confounding variables
Prednisone doses Disease duration
correlation 
coeffi cient (r)
p value correlation 
coeffi cient (r)
p value
Serum leptin 
concentration
- 0.1 0.41 0.326 0.006
Mex-SLEDAI 
score
0.396 0.001 -0.028 0.816
DISCUSSION
The median serum leptin concentration in normal BMI 
premenopausal woman with SLE was 13,4 (range : 0.6 – 45.9) 
ng/ml in this syudy. This result was lower than the result of 
Garcia-Gonzales et al study, which was 30 (range : 4 – 74) 
ng/ml, while Wislowska et al found the median serum leptin 
concentration was 7.5 (range : 1.8 – 66.3) ng/ml.1, 12 Both of 
these studies did not do subject selection based on BMI and 
menopausal status. Therefore these different results might 
be affected by those variables because of their effect on 
leptin concentration. Both of these studies showed median 
concentration of serum leptin in normal woman was 15 (range: 
2 – 59) ng/ml and 8.8 (range: 0.7 – 39.2) ng/ml. Several factors 
known to affect leptin concentration are gender, body weight, 
BMI and corticosteroid. This study only considered female 
subject to control the effect of gender on leptin concentration.
 Glucocorticoid increased leptin production in vitro 
and a hexogen glucocorticoid on human increased leptin 
concentration in the circulation.13,14 However, Tataranni 
et al found that either acute or prolonged administration of 
glucocorticoid (methylprednisolone)  did not affect plasma 
leptin concentration on human.15 Bokarewa et al reported 
that administration of disease-modifying antirheumatic drugs 
(DMARDs) such as methotrexate (MTX), sulfasalazine, 
azathioprine, cyclosporine, or tumor necrosis factor (TNF)-α 
inhibitor on rheumatoid arthritis patient affected plasma leptin 
concentration. They reported that subjects with DMARDs 
therapy beside MTX had low leptin concentration compared 
to subject who got MTX therapy. On the other hand, Harle et al 
reported that there was no change of leptin serum concentration 
on rheumatoid arthritis patient who got adalimunab (anti-TNF-
α) therapy.17 Teplan et al reported that subject who had kidney 
transplantation with long term mycophenolate mofetil therapy 
had a decrease plasma leptin concentration.18 In this study, 
we did not fi nd any difference on serum leptin concentration 
between subject received prednisone therapy only and subject 
received combination therapy of prednisone and another 
immunosuppressant. This result showed administration of 
another immunosuppressant combined with prednisone did 
not affect serum leptin concentration.
 A patient was considered to have an active disease 
activity if his/her Mex-SLEDAI score ≥ 2 points, and inactive 
disease activity if his/her Mex-SLEDAI score < 2 points.19 In 
this study, patients with active disease activity had median 
serum leptin concentration lower than patients with inactive 
disease activity. However this difference was not statistically 
signifi cant. There was no correlation found between serum 
leptin concentration and Mex-SLEDAI score in patients 
with active disease activity and patients with inactive disease 
activity (data wasn’t shown).
 In our study, a negative correlation was found between 
serum leptin concentration and disease activity (Mex-
SLEDAI score). However, this correlation was not statistically 
signifi cant. This result was similar with previous studies done 
by Gracia-Gonzales et al and Wislowska et al.1,12 Both of 
these studies resulted in a negative correlation between serum 
leptin concentration and the disease activity measured with 
Mex-SLEDAI respectively without statistic signifi cance. In 
this study, this result might be caused by : (1) Mex-SLEDAI 
score is a clinical instrument for disease activity, which does 
not refl ect changes on cytokines or hormones concentration 
that  infl uence the infl ammatory response; (2) Effects of 
confounding variables (prednisone doses and disease duration); 
and (3) Lack  of the study’s power (this study’s power was 
80%).
 Systemic lupus erythematosus is characterized by a 
predominantly humoral response (Th2 type) that leads to over 
expression of Th2 cytokines, such as IL-4 and IL-10.20 Th2 
immune responses leads to B cell hyperactivity and production 
of pathogenic auto antibodies, then fi nally,  tissue injury and 
damage.6,21,22 Leptin exerts inhibitory effects on Th2 cells 
which in turn decreases production of IL-4 and IL-10 and then 
reduces activation of B cells.5 This process causes decrease in 
disease activity.5,23 This  might explained   negative correlation 
between serum leptin concentration and disease activity found 
in our study. 
 Signifi cant negative correlation between serum leptin 
concentration and disease activity was found by Kümpers et al 
on the ANCA-associated Vasculitis study. In this study, disease 
activity was measured with CRP concentration, Birmingham 
Vasculitis Activity Score, and Circulating Endothelial Cells.24
 Experimental study conducted by Sarraf et al found 
that serum leptin concentration promptly increased during 
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acute infection and sepsis.25 It was consistent with raised 
leptin mRNA expression during acute infl ammation reaction 
stimulated by LPS and cytokines like TNF-α, IL-6 and IL-
1β. This result showed that these cytokines stimulated leptin 
release into circulation following acute infl ammation. On 
the other hand, Popa et al study on rheumatoid arthritis (RA) 
found negative correlation between serum leptin concentration 
and markers of infl ammation such as CRP and IL-6.26 The 
conclusion of their study was a signifi cant inverse correlation 
between infl ammation and leptin concentrations in active RA 
patients.26 This suggested that active chronic infl ammation 
may decrease plasma leptin concentrations.
 Bokarewa’s study on RA  showed that leptin concentration 
in synovial fl uid RA patients with erosive arthritis was lower 
than RA patients without erosive arthritis.27 They concluded 
that local consumption of leptin in the joint cavity was 
associated with non-erosive joint disease, suggesting that 
leptin has a protective role against the destructive course of 
RA.
 A cohort study done by van der Helm-van Mil et al 
showed that RA patients (anti-CCP positive) with high BMI 
(≥ 30 kg/m2) had lower disease activity than RA patients with 
BMI less than 30 kg/m2 during 3 years observation.28 They 
concluded a positive correlation between BMI and serum 
leptin concentration. Necla et al found a negative correlation 
between serum leptin concentration and presence of proteinuria 
in nephritic syndrome patients.29 Until now, there has not been 
any prospective study conducted to determine leptin role on 
prognosis of SLE patients. Therefore, further investigation is 
needed to evaluate whether leptin has protective or destructive 
effect on SLE patients.
 In this study, serum leptin concentration in SLE patients 
who had clinical picture of renal disorder, arthritis, vasculitis, 
mucocutaneous and hematologic disorder didn’t differ with 
SLE patients without those clinical picture. In contrary, 
Wislowska et al showed signifi cantly lower serum leptin 
concentration in SLE patients with clinical picture of arthritis 
or neurologic disorder than patients without this symptom.12
 The main variables (serum leptin concentration and Mex-
SLEDAI score) had a correlation with confounding variables 
(prednisone doses and disease duration) after being analyzed 
with statistic means. Serum leptin concentration had a positive 
correlation with disease duration, whereas Mex-SLEDAI had 
a positive correlation with prednisone doses. This suggested 
that our study results might be interfered with confounding 
variables.
 Our study had some limitations, including wide range of 
prednisone doses and disease duration made subjects became 
less homogeneous. There were also common limitations of 
cross-sectional study such as an unavoidable presence of 
the incidence-prevalence bias. It was diffi cult for a cross-
sectional study design to determine relation between leptin 
concentrations with clinical manifestations of SLE. Stronger 
designs such as cohorts and clinical trials allowed investigators 
to obtain better conclusions about effects of leptin on clinical 
manifestations in SLE patients.
 In conclusion, the result of this study showed no correlation 
between serum leptin concentration and disease activity in 
SLE premenopausal women with normal body mass index. 
Several confounding variables such as prednisone doses 
and disease duration might interfere to these results. Further 
investigations using stronger design are necessary to show the 
relation between serum leptin concentration and cytokines 
produced by Th1 and Th2 cells. It is better to conduct the 
study in new patients with normal BMI who haven’t received 
steroid therapy to minimize the confounding variables 
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